{"id":"W4296797608","doi":"10.1093/oncolo/oyac192","title":"Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Everolimus; Medicine; Clinical endpoint; Renal cell carcinoma; Internal medicine; Adverse effect; Oncology; Randomized controlled trial; Urology; Tolerability; Phases of clinical research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007510972,0.0003001131,0.001092399,0.0001371159,0.000176533,0.000007356977,0.0002470601,0.00006765081,0.0004611695],"category_scores_gemma":[0.00007073073,0.000168494,0.0002588684,0.0003330753,0.0003208031,0.00005114814,0.0001465362,0.0003570974,0.000004493251],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005102179,"about_ca_system_score_gemma":0.000295965,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002349448,"about_ca_topic_score_gemma":0.00002831224,"domain_scores_codex":[0.9971914,0.0007624048,0.0006355575,0.0003796633,0.0006522958,0.0003786621],"domain_scores_gemma":[0.9984628,0.0002995257,0.0004128513,0.0006170457,0.0001059871,0.0001018224],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.98151,0.00690397,0.005833479,0.00001890589,0.0001112398,0.0001443529,0.001109354,0.0001017915,0.001329385,0.000005248244,0.0001459055,0.002786319],"study_design_scores_gemma":[0.9072779,0.04960552,0.03445558,0.0000164058,0.000244037,0.000005549474,0.0001608992,0.00004250267,0.00740499,0.00003212995,0.0005796802,0.0001748129],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921189,0.0008110082,0.000005433426,0.000427159,0.0002146149,0.005029898,0.00005032325,0.00003231551,0.001310329],"genre_scores_gemma":[0.9971132,0.0000334986,0.0002347571,0.0003989493,0.00006805822,0.001495198,0.0001319214,0.00004141334,0.0004830333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07423215,"threshold_uncertainty_score":0.6870985,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01675006100570516,"score_gpt":0.2691139331315795,"score_spread":0.2523638721258744,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}